These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 18314425)

  • 1. Controversies surround heart drug study: questions about Vytorin and trial sponsors' conduct.
    Mitka M
    JAMA; 2008 Feb; 299(8):885-7. PubMed ID: 18314425
    [No Abstract]   [Full Text] [Related]  

  • 2. Amid lingering questions, FDA reprieves LDL cholesterol-lowering medication.
    Mitka M
    JAMA; 2009 Feb; 301(8):813-5. PubMed ID: 19244181
    [No Abstract]   [Full Text] [Related]  

  • 3. A case study of single-pill combination therapy: the ezetimibe/simvastatin combination for treatment of hyperlipidemia.
    Huang X; Chen DY
    ChemMedChem; 2012 Nov; 7(11):1882-94. PubMed ID: 22907901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In brief: Ezetimibe/simvastatin (Vytorin) in chronic kidney disease.
    Med Lett Drugs Ther; 2012 Jan; 54(1381):4. PubMed ID: 22233589
    [No Abstract]   [Full Text] [Related]  

  • 5. Ezetimibe + simvastatin (Merck/Schering-Plough).
    Flores NA
    Curr Opin Investig Drugs; 2004 Sep; 5(9):984-92. PubMed ID: 15503655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The SHARP trial: lessons learnt; answers and more questions!
    Turagam M; Velagapudi P
    Int J Cardiol; 2012 Apr; 156(1):e6. PubMed ID: 21849215
    [No Abstract]   [Full Text] [Related]  

  • 7. Ezetimibe/Simvastatin (vytorin) for hypercholesterolemia.
    Goldman-Levine JD; Bohlman LG
    Am Fam Physician; 2005 Nov; 72(10):2081-2. PubMed ID: 16342840
    [No Abstract]   [Full Text] [Related]  

  • 8. Critical lessons from the ENHANCE trial.
    Greenland P; Lloyd-Jones D
    JAMA; 2008 Feb; 299(8):953-5. PubMed ID: 18314439
    [No Abstract]   [Full Text] [Related]  

  • 9. Lipid-lowering effects of ezetimibe and simvastatin in combination.
    Ijioma N; Robinson JG
    Expert Rev Cardiovasc Ther; 2011 Feb; 9(2):131-45. PubMed ID: 21453210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Ezetimibe: caution in the face of doubt].
    Araujo F; Mateo de Castro J; Encinas Barrios C
    Farm Hosp; 2010; 34(4):212-4. PubMed ID: 20153227
    [No Abstract]   [Full Text] [Related]  

  • 11. Ezetimibe plus moderate-dose simvastatin after acute coronary syndrome: what are we IMPROVEing on?
    DiNicolantonio JJ; Chatterjee S; Lavie CJ; Bangalore S; O'Keefe JH
    Am J Med; 2015 Aug; 128(8):914.e1-4. PubMed ID: 25731133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aortic stenosis: look globally, think globally.
    Pibarot P; Dumesnil JG
    JACC Cardiovasc Imaging; 2009 Apr; 2(4):400-3. PubMed ID: 19580720
    [No Abstract]   [Full Text] [Related]  

  • 13. Surrogate end points and FDA approval: a tale of 2 lipid-altering drugs.
    Psaty BM; Lumley T
    JAMA; 2008 Mar; 299(12):1474-6. PubMed ID: 18364491
    [No Abstract]   [Full Text] [Related]  

  • 14. Cholesterol drug controversy continues.
    Mitka M
    JAMA; 2008 May; 299(19):2266. PubMed ID: 18492963
    [No Abstract]   [Full Text] [Related]  

  • 15. Premature release of data from clinical trials of ezetimibe.
    Califf RM; Harrington RA; Blazing MA
    N Engl J Med; 2009 Aug; 361(7):712-7. PubMed ID: 19675335
    [No Abstract]   [Full Text] [Related]  

  • 16. Vytorin: a combination of ezetimibe and simvastatin.
    Med Lett Drugs Ther; 2004 Sep; 46(1191):73-4. PubMed ID: 15365507
    [No Abstract]   [Full Text] [Related]  

  • 17. In brief: Zetia and Vytorin: the ENHANCE study.
    Med Lett Drugs Ther; 2008 Jan; 50(1278):5. PubMed ID: 18219263
    [No Abstract]   [Full Text] [Related]  

  • 18. Ezetimibe and recent clinical trials: a look on the bright side.
    Ahmed MH
    Expert Opin Drug Saf; 2010 Jul; 9(4):511-4. PubMed ID: 20377476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease.
    Farnier M; Retterstøl K; Steinmetz A; Császár A
    Diab Vasc Dis Res; 2012 Jul; 9(3):205-15. PubMed ID: 22228773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes.
    Cannon CP; Giugliano RP; Blazing MA; Harrington RA; Peterson JL; Sisk CM; Strony J; Musliner TA; McCabe CH; Veltri E; Braunwald E; Califf RM;
    Am Heart J; 2008 Nov; 156(5):826-32. PubMed ID: 19061694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.